A phase I clinical trial on intratumoral injection of autologous CD1c (BDCA-1)+ / CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec (T-VEC) in patients with advanced pretreated melanoma

Schwarze, J. K. (Presenter), Tijtgat, J. (Contributor), Awada, G. (Contributor), Cras, L. (Contributor), Dufait, I. (Contributor), Forsyth, R. (Contributor), Tuyaerts, S. (Contributor), Neyns, B. (Contributor)

Activity: Talk or presentationTalk or presentation at a conference


Mini oral presentation in the "Investigational Immunotherapy" session
Period17 Sep 2021
Event titleESMO Congress 2021
Event typeConference
LocationParis, France
Degree of RecognitionInternational